Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial

(2020) Keyur Patel et al.   HEPATOLOGY

Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials

(2020) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

(2019) Arun J. Sanyal et al.   HEPATOLOGY

Noninvasive tests accurately identify advanced fibrosis due to NASH : Baseline data from the STELLAR trials

(2019) Quentin M. Anstee et al.   HEPATOLOGY

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

(2019) Stephen A. Harrison et al.   JOURNAL OF HEPATOLOGY

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis

(2018) Eric J. Lawitz et al.   Clinical Gastroenterology and Hepatology

Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis

(2018) Stephen A. Harrison et al.   GASTROENTEROLOGY

Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents

(2018) Leigh Goedeke et al.   HEPATOLOGY

Combination of an FXR agonist and an ACC inhibitor increases anti-fibrotic efficacy in rodent models of NASH

(2018) J. Bates et al.   JOURNAL OF HEPATOLOGY

Proof of concept study of an apoptosis-signal regulating kinase (ASK1) inhibitor (selonsertib) in combination with an acetyl-CoA carboxylase inhibitor (GS-0976) or a farnesoid X receptor agonist (GS-9674) in NASH

(2018) E. Lawitz et al.   JOURNAL OF HEPATOLOGY

FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver

(2018) Romeo Papazyan et al.   JOURNAL OF LIPID RESEARCH

Ductular reaction in liver diseases: pathological mechanisms and translational significances

(2018) Keisaku Sato et al.   HEPATOLOGY

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

(2018) Rohit Loomba et al.   GASTROENTEROLOGY

Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study

(2017) Kathryn Stiede et al.   HEPATOLOGY

Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis

(2017) A. Sanyal et al.   JOURNAL OF HEPATOLOGY

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

(2016) Yaron Rotman et al.   GUT

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

(2016) Zobair M. Younossi et al.   HEPATOLOGY

The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH

(2015) Rohit Loomba et al.   GASTROENTEROLOGY

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease

(2013) Victoria L. Gadd et al.   HEPATOLOGY